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This study was carried out in the outpatient unit of the Teaching Hospital of the University of São Paulo 
(USP), and studied the impact of an educational program aimed at improving hypertensive patients’ 
compliance to treatment. Seventy five (75) hypertensive patients of both sexes took part in the study 
which had no age or race discrimination. Participants presented no other concomitant pathology, except 
obesity, diabetes and dyslipidemia. Forty one patients were allocated to an experimental group (EG). 
Experimental patients attended lectures on the use of medication and artery hypertension (AH) and 
received personal pharmaceutical guidance for nine months. The control group (CG) comprised 34 
patients who did not attend lectures or receive pharmaceutical advice in this period. The results were 
assessed by means of serum levels of cholesterol and fractions of tryacylglicerol (TG), urine sodium and 
potassium, arterial pressure (AP), body mass index (BMI), waist-hip ratio (WHR), and also based on 
responses to a questionnaire focusing on AH and treatment. Patients who received the guidance showed 
a greater decrease in AP, TG and WHR, besides an increase of potassium excretion through urine. The 
experimental group also scored higher on the questionnaires compared to the CG. It was concluded that 
the educational process, applied under the conditions of the present study, improves clients’ clinical 
response to antihypertensive treatment and should be included in therapeutic strategies of health care 
services dealing with hypertensive patients.
Uniterms: Arterial hypertension/adhesion to treatment. Health Education. Pharmaceutical Care.
Este trabalho, realizado no ambulatório do Hospital Universitário da USP, estudou a repercussão de um 
programa educacional visando melhorar a adesão do paciente hipertenso ao tratamento. Participaram 
do trabalho 75 pacientes de ambos os sexos, sem discriminação de idade ou raça, sem outras patologias 
concomitantes, exceto obesidade, diabetes e dislipidemia. Quarenta e um pacientes assistiram palestras 
sobre uso de medicamentos e hipertensão arterial (HA), receberam orientação farmacêutica individualizada 
durante nove meses e foram denominados grupo experimental (GE); o grupo controle (GC), composto 
por 34 pacientes não assistiu palestras nem recebeu orientação farmacêutica, neste período. Os resultados 
foram avaliados por meio de níveis séricos de colesterol e frações, triacil-gliceróis (TG), sódio e potássio 
urinários, pressão arterial (PA), índice de massa corpórea (IMC), relação cintura/quadril (RCQ), além de 
respostas a questionário enfocando HA e tratamento. Verificou-se que os pacientes orientados apresentaram 
maior decréscimo da PA, TG e da RCQ, além de aumento da excreção urinária de potássio e do percentual 
de acertos em questionários, em relação ao GC. Concluiu-se que o processo educativo, utilizado nas 
condições deste estudo, melhora a resposta clínica do paciente ao tratamento anti-hipertensivo e deve 
fazer parte das estratégias terapêuticas de serviços de atendimento a pacientes hipertensos.
Unitermos: Hipertensão arterial/adesão ao tratamento. Educação em Saúde. Atenção Farmacêutica.
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INTRODUCTION
Arterial hypertension is a condition characterized 
by a chronic increase in arterial pressure, which inter-
nationally is considered higher than the normal limit of 
120 mmHg for systolic arterial pressure, and 80 mmHg for 
diastolic pressure. According to the Joint National Com-
mittee (2004), individuals with systolic arterial pressure in 
the range 120-139 mmHg and/or diastolic arterial pressure 
of around 80-89 mmHg are classified as pre-hypertensive 
while those with levels above 140/90 mmHg are classified 
as hypertensive. Several factors predispose individuals 
to AH, the main ones being hereditary cause, race, sex, 
age, excessive use of salt, obesity and sedentarism. The 
prevalence of AH is estimated at 20% of the world adult 
population, plus a significant number of children and 
adolescents who may harbor the disease. AH is one of the 
main risk factors for cardiovascular diseases, causing 40% 
of deaths by cerebrovascular accident and 25% by coronary 
disease, according to Quinta (2006). The disease increases 
with age and is found in about 50% of individuals aged over 
55 years (Hermansen, 2000). In a study by Johnson (1999), 
over 500,000 cerebrovascular accidents and one million 
myocardial infarctions were found to be registered each 
year by the US National Center of Health Statistics as a 
result of this pathology.
This condition is also responsible for some 40% 
of cases of early retirement and a significant number 
of absences from work, causing not only serious health 
problems in patients but also a high social cost (Terceiro, 
1998).
There is a sufficient arsenal of therapeutic options 
to allow the control of arterial pressure in all hyperten-
sive individuals. However, the percentage of success of 
antihypertensive therapeutics is far from ideal. One of 
the causes of this failure in the treatment of hypertensive 
individual is the lack of compliance with the recommen-
dations given to patients, according to Basile, Nichols-
English, Waeber (2000). Treatment noncompliance by 
patients with chronic diseases is a major problem in public 
health of epidemic proportions, and is called the invisible 
epidemic. Patient compliance to therapeutic treatment can 
also be defined, according to Burnier (2000), as the faithful 
compliance with medication or non-medication treatment 
prescribed by doctors or other health professionals. Non-
medication treatment includes dietary/nutritional recom-
mendations, physical exercises and obesity correction, and 
involves alterations to one’s lifestyle, according to Korhonen 
(1999) and Weier (2000).
Compliance to altering one’s lifestyle, according to 
Margetts (1999), may cause a substantial impact in the re-
duction of morbidity and mortality of the population with 
this chronic condition. Neutel (1999) carried out studies 
on the prevalence of hypertension in the adult population 
in the US, and found that only 27% of patients follow 
the hypertensive treatment correctly, and managed to 
keep their arterial pressure under control. It is estimated 
that about half of the 2 billion medication prescriptions 
made out for hypertension treatment worldwide every 
year are incorrectly followed. Brouker (2000) reported 
that one sixth of all hospital admissions and 2.5 million 
cases seen in emergency rooms every year involve hyper-
tensive patients who are not compliant to the treatment. 
Also, according to Heisler (2008), the results of low 
compliance to treatment may be evidenced by the incre-
ase in prescription of doses that are unnecessary for the 
treatment, or by changes in medication, even when these 
are unable to keep the arterial pressure within normal 
levels, and cause an increase in the number of avoidable 
hospital admissions of hypertensive patient cases which 
consequently raises the costs of health care for both the 
patient and government agencies.
Pharmaceutical Care has been defined in terms of the 
World Health Organization (2002), as “a model of phar-
maceutical practice developed in the Pharmaceutical Care 
context. It comprises attitudes, ethical values, behaviors, 
commitments and co-responsibilities in the prevention of 
diseases, promotion and recovery of health, in a way that 
is integrated with health teams. It is the direct interaction 
between pharmacists and users, with a view to achieving 
rational pharmacotherapy and obtaining defined and me-
asurable results which translate to improvement in life 
quality”.
According to Ivama, Jaramillo (2008) and Bonal 
(2008), Pharmaceutical Care, one characteristic of 
which is the interaction between the pharmacist and 
the members of a multidisciplinary team, is an integral 
part of health care and does not encroach on the area of 
other health agencies. In fact, the opposite is true in that 
it is indispensable for the global health care of patients, 
being a practice already adopted in several countries. 
In this context, Storpirtis et al. (2008) note that USP’s 
University Hospital develops activities on education, 
research and assistance, encouraging multidisciplinary 
health work. 
OBJECTIVE
The aim of this work was to assess the impact of an 
educational program on the compliance of hypertensive 
patients with medication and non-medication treatment at 
USP University Hospital (HU-USP).
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METHODS
Patient selection and formation of groups
HU-USP outpatients of both sexes were recruited in 
the period spanning from March to December, 2001. Inclu-
sion criteria were no age limit or restriction on race, and 
absence of other concomitant pathology, except obesity, 
diabetes and dyslipidemia. Recruitment was performed in 
the order that patients were discharged from the medical 
care service, and carried out by means of interviews. In-
terviews included an introduction by the interviewer, pre-
sentation of the goal of the work and an explanation on the 
importance of the study to be carried out. To set up the EG, 
patients were invited to take part in the educational pro-
gram, namely, lectures and provision of individual pharma-
ceutical advice. Individuals who agreed to take part were 
assigned to the EG (n = 41) in which the educational pro-
gram was applied. Members of the control group (n = 34) 
were invited to take part in the study, signed the written 
informed consent form, but were not invited to take part 
in the lecture or offered individual advice. Randomizing 
criterion was not utilized in forming the EG and CG.
Patients from the experimental and control groups 
answered a questionnaire, in their first contact with the 
pharmacist in charge of the program, which focused on 
general knowledge of AH. The same questionnaire was 
completed again 270 days after the initial contact to com-
pare the results. From this first contact, patients were given 
advice on how to collect 24 hour urine samples, and also 
on taking arterial pressure, measuring cardiac rate (CF), 
waist and hip circumference and height. Patients of the 
experimental group were asked to return to the clinic to 
attend the first lecture of the educational program.
All participants of the study signed the written infor-
med consent form approved by the Research Ethics Com-
mittee of USP University Hospital, under number 216/01.
Educational program applied to the experimental 
group
The experimental group received guidance by 
means of lectures and also on a one-to-one basis. The lec-
tures were presented to the participants in clear and easy 
language, with illustrative didactic material (slides and 
educational brochures) and were divided into three parts:
·	 information on the disease, emphasizing its risks 
when not controlled, and the potential benefit of the 
non-medication treatment.
·	 notions on antihypertensive medication, duration of 
effect, interaction with other medication and food, 
most frequent adverse reactions, and emphasis on 
the potential benefit expected from medication and 
non-medication treatment, according to Urquhart 
(2000).
·	 discussion on the contents of the questionnaire used 
in the interview.
The three lectures were given to groups of about 
10 patients, at intervals of approximately 2 to 4 months, 
depending on their ability to attend. During these returns 
for the lectures, measures of arterial pressure, cardiac rate, 
weight, waist and hip circumference were taken and indi-
vidual advice given when necessary. The control group did 
not take part in the lectures or receive individual advice.
Assessment of treatment compliance
Assessment of the results was carried out in the two 
experimental and control groups by means of the following 
procedures:
Arterial pressure measurement: all patients had 
their arterial pressure (AP) measured in a seated position, 
with mercury or aneroid sphygmomanometer graded by 
INMETRO, according to the Joint National Committee’s 
recommendations (1997).
Height, waist and hip circumference weight and 
measures: both the weighing with patients in shoes, coats 
and empty pockets, and measures of height were perfor-
med on a set of hospital scales, whereas a new universal 
measuring tape was used to take waist and hip circumfe-
rence measures.
Total, fraction and tryacylglicerol serum cholesterol 
concentrations: the total and fraction serum concentrations 
(High-Density lipoproteins and Low- density lipoproteins) 
as well as tryacylglicerol (TG), were carried out within 
the Clinical Laboratory Service of the HU-USP by the 
methods:
·	 Total cholesterol: enzymatic Trinder method with 
Ames kit;
·	 HDL: direct, without precipitation in immunoassay 
with Diasys kit;
·	 LDL: through calculations;
·	 TG: GPO-PAP Trinder with Merck kit.
The results of these determinations were obtained 
from HU-USP patients' medical records.
Sodium and potassium levels excreted in 24-hour 
urine: in order to better assess the amount of sodium and 
potassium taken by the patient at the end of, and during the 
week, samples of 24-hour urine were requested and collec-
ted on three different days: Sunday, Monday and Tuesday. 
Concentration of sodium and potassium from the 24-hour 
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urine were measured by flame-emission spectrophometry. 
The sodium and potassium urine concentration (mmol/liter) 
was multiplied by the volume of 24-hour diuresis (li-
ters) to calculate the daily excretion of these electrolytes 
(mmol/24 hours). The arithmetic mean of the three daily 
amounts was calculated for purposes of statistical analysis.
Questionnaire: The previously validated questio-
nnaire was applied to patients in the first interview and 
again after the educational process. The scale compri-
sed two parts with guided questions: the first part had 
15 yes/no-type questions on general, basic aspects on AH, 
and the second part had 7 questions which assessed whe-
ther the patient considered themselves compliant or not 
with the treatment, where answers offered three options 
(yes, no and I am not in treatment). 
Periodicity of data collection
Variable follow-up: Arterial Pressure (AP), CF, Wei-
ght, Height and Body Mass Index (BMI) were recorded 
at 120, 180 and 270-day intervals after the first contact 
with patients. Regarding waist/hip ratio, serum dosages 
of total and fraction cholesterol, triacylglycerol, sodium 
and potassium concentrations excreted in 24-hour urine 
and percentage of correct answers on the questionnaires, 
data from the period of the first interview and after 270 
days were collected.
Patient grouping
Although the experimental and control group pa-
tients were all hypertensive, they were divided into three 
groups for the purpose of analysis:
·	 Experimental group (EGT) and total control group 
(CGT) comprised all patients of the group.
·	 Experimental group (EGH) and intense control 
group (CGH) comprised patients with non-control-
led arterial pressure.
·	 Experimental group (EGN) and normotensive con-
trol group (CGN) comprised patients with controlled 
arterial pressure.
The separation of patients with controlled arterial 
pressure from those with no arterial pressure was impor-
tant to best assess the results.
Statistical treatment
The results were expressed as means ± standard 
deviation (M ± SD). The significance level considered 
was 5%. The following tests were utilized to analyze the 
variables of the present study: Paired Student's t-test; Non-
paired Student's t-test; Mann-Whitney and Kruskal-Wallis 
nonparametric tests; Spearman’s coefficient correlation 
and logistic regression.
RESULTS
The experimental and control group population 
were studied to determine their composition, in terms of 
the following qualitative variables: sex, race, age group, 
marital status, education, professional activity, salary 
range, smoking, alcoholism, physical activity (Table I). 
The following quantitative variables were also analyzed: 
systolic arterial pressure (SAP), diastolic arterial pres-
sure (DAP), cardiac rate (CR), weight, body mass index 
(BMI), waist/hip ratio (W/H), total cholesterol, high den-
sity lipoprotein (HDL), low density lipoprotein (LDL), 
triacylglycerols (TG), sodium excretion in 24-hour urine 
(UnaV) and potassium in 24-hour urine (UKV), 24-hour 
sodium/potassium excretion ratio (UNaV/UKV) and score 
on questionnaire (Table II). Compliance of the study pa-
tients with antihypertensive treatment was also evidenced 
by their attendance to lectures and/or to deliver their urine 
samples for potassium measures, on the agreed dates, be-
sides the answers to questionnaires. Out of the 41 patients 
in the experimental group, 71% attended the lectures and 
62% attended the 2nd phase of the 24-hour urine exam, 
while 72% of the control group completed the 2nd phase 
of the 24-hour urine exam. 
Obesity was detected (BMI over 30) in 44% of 
patients in the experimental group (EG) and 35% in the 
control group (CG); 15% of diabetic patients were found 
in the EG and 12% in the CG, while 17% of patients had 
high cholesterol (levels above 240 mg/dL (Blumenthal, 
2000), in the EG and 44% in the CG.
Out of the 41 patients comprising the experimental 
group, 51% showed at study baseline, an AP higher or 
close to 140 X 90 mmHg, whereas in the control group the 
percentage found was 71%. In the EG and the CG, 48% 
and 21% of patients, respectively, who had an AP higher 
or close to 140 X 90 mmHg at baseline, were successful 
in normalizing AP. However, approximately 10% of the 
patients of both groups considered themselves noncom-
pliant, according to their answers to the questionnaires. 
AP in EGN and CGN remained under control.
Approximately 12% of patients in both the EG and 
the CG groups controlled AP without medication through 
changes in lifestyle. Out of those who took antihypertensi-
ve medication, approximately 40% had monotherapy and 
around 30% had treatment with 2 medications, a diuretic 
medication associated with a beta-blocker, inhibitor of 
ACE or calcium channel antagonist. The association of 
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three, four or up to five of the medications outlined were 
prescribed if necessary for most patients. No correlation 
between the use of a given kind or association of medica-
tions and its dosage, and AP control was found.
Analysis of the percentage variation of the studied 
quantitative variables in the period of 270 days in the expe-
rimental and control hypertension, normotension and total 
groups, revealed significant differences for five variables. 
The arterial (systolic and diastolic) pressures decreased 
in the hypertensive experimental group; the triacylglyce-
rol amounts decreased in the total experimental group; 
the waist/hip ratio fell in the hypertensive experimental 
group, whereas the potassium urine excretion in 24-hour 
volume increased in the total experimental group, and the 
percentage of correct responses on the questionnaires also 
increased in the normotensive experimental group, all in 
comparison to the respective control groups. No significant 
differences were seen for the other variables studied.
Systolic and diastolic arterial pressure
A significant percentage fall in arterial pressure 
was noted (SAP and DAP) in the EGH. SAP showed a 
-8.8±10.5 variation in the EGH vs. 1.1±5.3 in the CGH 
(p=0.0005) (Figure 1), and DAP showed a -9.4±8.6 
variation in the EGH vs. -2.7±5.7 in the CGH (p=0.01) 
(Figure 2). 
Waist/hip ratio
EGH vs. CGH showed a significant difference for 
these variables, which decreased in the experimental groups 
TABLE I - Profile of experimental and control group total populations
Qualitative variables Grouping Experimental Group 
n = 41
Control Group 
n=34
% N % N
Sex Female 70.7 29 52.9 18
Male 29.3 12 47.1 16
Race Non Caucasian 39.0 16 38.2 13
Caucasian 61.0 25 61.8 21
Age Group 31 to 50 years 36.6 15 35.3 12
51 to 70 years 46.3 19 52.9 18
Above 70 years 17.1 07 11.8 04
Marital Status Married 82.9 34 79.4 27
Single 17.1 07 20.6 07
Education Up to full 1st year 68.3 28 70.6 24
From secondary school unfinished 31.7 13 29.4 10
Professional activity Did not work 41.5 17 32.4 11
Worked 58.5 24 67.6 23
Salary rate 1- 5 39.0 16 44.1 15
(minimum wages) 5-10 29.3 12 35.3 12
> 10 31.7 13 20.6 07
Smoking Smoking 17.1 07 23.5 08
Non smoking 82.9 34 76.5 26
Alcoholism 1 (Yes) 12.2 05 17.6 06
2 (No) 87.8 36 82.4 28
Physical activity 1 (Yes) 43.9 18 44.1 15
2 (No) 56.1 23 55.9 19
Heredity Yes 82.9 34 79.4 27
No 9.8 04 17.7 06
Does not know 7.3 03 2.9 01
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FIGURE 1 - Percentage change ± SD in systolic arterial pressure 
between time 0 and the arithmetic mean of measures after 120, 
180 and 270 days in the hypertensive experimental group (EGH) 
and hypertensive control group (CGH). *p=0.0005. EGH n=21 
(21 patients in EG with SAP above 140 mmHg on the 1st AP 
measurement); CGH n=24 (24 patients in CG with SAP above 
140 mmHg on the 1st AP measure).
FIGURE 2 - Percentage change ± SD of diastolic arterial pressure 
between time 0 and the arithmetic mean of the measures after 
120, 180 and 270 days in the hypertensive experimental group 
(EGH) and hypertensive control group (CGH). *p=0.01EGH 
n=17 (17 patients in EG with SAP above 90 mmHg on the 1st 
AP measure); CGH n=19 (19 patients of CG with DAP above 
90 mmHg on the 1st AP measure).
TABLE II – Baseline values for Quantitative variables in the total experimental and control groups
Qualitative variables Control Group TOTAL Control Group TOTAL
Mean±SD  N Mean±SD  N
Systolic arterial pressure (mmHg) 144±19.6 41 147±16.1 34
Diastolic arterial pressure (mmHg) 89±11.7 41 92±13.1 34
Cardiac rate (bpm) 70±8.6 41 72±11.5 34
Weight (kg) 72.3±14.4 40 72.9±14.1 32
Body mass index (kg/m2) 29.2±5.1 40 28.5±4.2 32
Waist/hip ratio 0.87±0.07* 29 0.92±0.09 24
Total cholesterol (mg/dL) 205.6±28.4 19 197.0±44.55 14
High density lipoprotein (mg/dL) 49.5±12.4 19 48.6±12.1 14
Low density lipoprotein (mg/dL) 130.2±21.8 19 125.5±27.5 13
Triacylglycerols (mg/dL) 130.3±39.8 18 124.3±52.7 15
Sodium urine excretion in 24-hour volume (mEq/24 hours) 144.1±45.8*** 24 190.3±55.8 24
Urine potassium excretion in 24-hour volume (mEq/24 hours) 47.9±16.0** 24 60.7±21.5 24
24-hour sodium and urine potassium excretion ratio 3.1±1.0 24 3.4±1.2 24
Questionnaire score (percentage correct) 87.6±9.0 29 85.3±6.8 24
Amounts expressed as mean ± standard deviation. *P<0.05 X control, **P=0.02, ***P<0.01 X control
and increased in the control groups. EGH had a percentage 
change of -1.3±2.7 X3.5±4.7 of CGH (p=0.001) (Figure 3). 
Triacylglycerols (triglycerides)
Triacylglycerol amounts decreased in the EGT and 
increased in the CGT. There was a significant percentage 
difference for this variable, with amounts of -1.9±31.7 
and 48.7±71.3 for EGT and CGT, respectively (p<0.05) 
(Figure 4).
Urine potassium excretion in 24-hour volume
The EGT showed a greater increase in potassium 
excretion compared to the CGT. There was a percentage 
difference for this variable between the EGT and CGT, 
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with amounts of 26.1±37.6 and 1.2±29, respectively 
(p<0.05) (Figure 5).
Percentage of correct responses on 
questionnaires
The experimental group of normotensive patients 
performed better in terms of the percentage of right 
answers than did the respective control group. EGN vs. 
FIGURE 3 - Percentage change ± SD of the waist/hip ratio 
between time 0 and 270 (days), in the hypertensive experimental 
group (EGH) and hypertensive control group (CGH). *p=0.001. 
EGH n=12 (12 patients of the hypertensive experimental group 
provided measures needed for comparisons). CGH n=16 (16 
patients of the hypertensive control group provided measures 
needed for comparisons).
FIGURE 4 - Percentage change ± SD of tryacylglicerol between 
time 0 and 270 (days) in the experimental group (EGT) and total 
control group (CGT). *p<0.05. EGT n=18 (18 patients of the 
total experimental group attended the required exam sessions). 
CGT n= 15 (15 patients of the total control group attended the 
required exam sessions). 
FIGURE 5 - Percentage change ± SD in 24-hour urine potassium 
excretion (UKV) between time 0 and 270 (days) in the total 
experimental group (EGT) and total control group (CGT). 
*p<0.05. EGT n=24 (24 patients of the total experimental group 
attended the required exam sessions). CGT n= 24 (24 patients 
of the total control group attended the attended the required 
exam sessions). 
FIGURE 6 - Percentage change ± SD in correct responses 
on questionnaires between time 0 and 270 (days) in the 
normotensive experimental group (EGN) and normotensive 
control group (CGN). *p<0.006. EGN n=16 (16 patients of 
the normotensive experimental group attended the sessions 
to answer the questionnaire). CGN n=07 (7 patients of the 
normotensive control group attended the sessions to answer 
the questionnaire).
CGN showed a percentage difference of 5.9±10.8 vs. 
-12.4±19.3 (p=0.006), i.e., in the control group there was 
a decrease in the number of correct answers (Figure 6).
DISCUSSION
Of the variables studied and outlined, the following 
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showed significant results: AP, triglycerides, waist/hip 
reaction, urine potassium excretion in 24-hour volume and 
percentage of correct answers on questionnaires.
In the hypertensive experimental group, there was 
a significant percentage decrease in systolic and diastolic 
pressures (Figures 1 and 2), with results comparable to 
those found by Mcgowan (2008); the same group showed 
a significant decrease in waist/hip ratio (Figure 3), which 
suggests greater compliance with the treatment by the 
hypertensive patients of the experimental group.
The reduction in the amounts of triacylglycerol in 
the EGT alone (Figure 4), did not indicate a change in food 
habits with fat restrictions, since the other serum lipids did 
not suffer a significant alteration in the studied population. 
However, it is possible to deduce that there was a change 
in the habits regarding physical activities, based on the 
decrease in waist/hip ratio and triacylglycerols.
 With regard to the significant increase in urine 
excretion of potassium in the EG, it is possible that these 
patients complied with the advice on food habit changes, 
increasing their intake of potassium-rich fruit and vegeta-
bles; notably the patients from both the EG and CG used 
the following types of medication to control AH: adrenergic 
beta-blockers, antagonists of calcium channel, angiotensin 
converting enzyme (ACE) inhibitors, angiotensin II AT1 
receptor antagonists, peripheral vasodilation action, besides 
thiazidic diuretics that promote the increase of urine potas-
sium excretion. However, 59% of the patients in the EG who 
had increased potassium urine secretion were not in use of 
thiazidic diuretics; likewise, in the CG, 55% of the patients 
who showed an increase in urine potassium excretion were 
not using this type of medication. It is also noteworthy that, 
among the population of EG patients who did not show an 
increase in urine potassium excretion, 56% used IECA or 
ARA II or aldosterone antagonist diuretics (medications 
that decrease urine potassium excretion) compare with 
39% of the CG population that did not show an increase in 
urine potassium excretion, thus reinforcing the possibility 
of changes in food habits in the EG (Figure 5).
The increase in correct answers on EG questionnai-
res suggests assimilation of the information given during 
the teaching process. EG normotensive patients showed 
more satisfactory results in answers on the questionnaires 
than did the CG patients (Figure 6). They were possibly 
responsible for the increase of correct answers observed 
in total experimental group questionnaires, since the 
hypertensive patients of the experimental group showed 
no increase in the percentage of correct answers in the 
studied period.
Several studies in the literature such as those by 
Dobs (1994) and Roca-Cusachs (1991), show that edu-
cation is a process and, as such, cannot change patient’s 
attitudes overnight, attitudes which have often been ingrai-
ned for decades. However, the evolution of the variables 
studied in the patients of the present study suggests that the 
knowledge acquired in the educational process increased 
patients’ awareness, motivating them to continue com-
plying with the advice received. This change in behavior 
was also observed by Green (2008), who showed that 
Pharmaceutical Care, applied for 12 months, although 
given over the Internet, resulted in better control of AH 
(in 56% of patients) in comparison to patients who did not 
receive guidance (31 to 36%). The present study found 
similar results in terms of AP control, which was achieved 
in 48% of the experimental patients versus 21% of the 
control patients). This study investigated the effectiveness 
of education as a preventive measure in the fight against 
the devastating effects of nontreated or poorly-treated 
AH, indicating that it is possible to improve adherence 
to treatment and, as a result achieve controlled clinical 
and laboratorial results by means of educational practices 
(Green, 2008; McGowan, 2008; Collins, 1999).
CONCLUSION
The educational process applied under the conditions 
of the present study, improves clients’ clinical response to 
antihypertensive treatment, and should be included in the 
therapeutic strategies of health care services dealing with 
hypertensive patients.
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